These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 26502922)
21. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167 [TBL] [Abstract][Full Text] [Related]
23. Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. Ouaïssi M; Silvy F; Loncle C; Ferraz da Silva D; Martins Abreu C; Martinez E; Berthézene P; Cadra S; Le Treut YP; Hardwigsen J; Sastre B; Sielezneff I; Benkoel L; Delgrande J; Ouaissi A; Iovanna J; Lombardo D; Mas E PLoS One; 2014; 9(9):e108520. PubMed ID: 25275504 [TBL] [Abstract][Full Text] [Related]
24. Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1. Pan Y; Wang L; Kang SG; Lu Y; Yang Z; Huynh T; Chen C; Zhou R; Guo M; Zhao Y ACS Nano; 2015 Jul; 9(7):6826-36. PubMed ID: 26083726 [TBL] [Abstract][Full Text] [Related]
25. Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients' Survival. Levidou G; Gajdzis P; Cassoux N; Donizy P; Masaoutis C; Gajdzis M; Gardrat S; Pergaris A; Danas E; Klijanienko J; Theocharis S Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638249 [TBL] [Abstract][Full Text] [Related]
26. Expression profile of class I histone deacetylases in human cancer tissues. Nakagawa M; Oda Y; Eguchi T; Aishima S; Yao T; Hosoi F; Basaki Y; Ono M; Kuwano M; Tanaka M; Tsuneyoshi M Oncol Rep; 2007 Oct; 18(4):769-74. PubMed ID: 17786334 [TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? Koutsounas I; Giaginis C; Theocharis S World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354 [TBL] [Abstract][Full Text] [Related]
28. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
29. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Pluemsampant S; Safronova OS; Nakahama K; Morita I Int J Cancer; 2008 Jan; 122(2):333-41. PubMed ID: 17935135 [TBL] [Abstract][Full Text] [Related]
30. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Minamiya Y; Ono T; Saito H; Takahashi N; Ito M; Mitsui M; Motoyama S; Ogawa J Lung Cancer; 2011 Nov; 74(2):300-4. PubMed ID: 21466904 [TBL] [Abstract][Full Text] [Related]
31. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer. Zhao B; He T Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499 [TBL] [Abstract][Full Text] [Related]
32. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ouaïssi M; Sielezneff I; Silvestre R; Sastre B; Bernard JP; Lafontaine JS; Payan MJ; Dahan L; Pirrò N; Seitz JF; Mas E; Lombardo D; Ouaissi A Ann Surg Oncol; 2008 Aug; 15(8):2318-28. PubMed ID: 18506539 [TBL] [Abstract][Full Text] [Related]
33. Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells. Gao DJ; Xu M; Zhang YQ; Du YQ; Gao J; Gong YF; Man XH; Wu HY; Jin J; Xu GM; Li ZS Pancreas; 2010 Oct; 39(7):994-1001. PubMed ID: 20467347 [TBL] [Abstract][Full Text] [Related]
34. The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma. Song S; Wang Y; Xu P; Yang R; Ma Z; Liang S; Zhang G Int J Oncol; 2015 Nov; 47(5):1819-28. PubMed ID: 26412386 [TBL] [Abstract][Full Text] [Related]
35. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity. Kim SO; Kim MR Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610 [TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Hofer MD; Chang MC; Hirko KA; Rubin MA; Nosé V Mod Pathol; 2009 Jul; 22(7):933-9. PubMed ID: 19377441 [TBL] [Abstract][Full Text] [Related]
37. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Weichert W; Röske A; Gekeler V; Beckers T; Stephan C; Jung K; Fritzsche FR; Niesporek S; Denkert C; Dietel M; Kristiansen G Br J Cancer; 2008 Feb; 98(3):604-10. PubMed ID: 18212746 [TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4, and -5 in Ovarian Adenocarcinomas. Levidou G; Arsenakis D; Bolovis DI; Meyer R; Brucker CVM; Papadopoulos T; Theocharis S Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790909 [TBL] [Abstract][Full Text] [Related]
39. Platelet-activating factor (PAF) receptor expression is associated with histopathological stage and grade and patients' survival in gastric adenocarcinoma. Giaginis C; Kourou E; Giagini A; Goutas N; Patsouris E; Kouraklis G; Theocharis S Neoplasma; 2014; 61(3):309-17. PubMed ID: 24824933 [TBL] [Abstract][Full Text] [Related]
40. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Weichert W; Röske A; Gekeler V; Beckers T; Ebert MP; Pross M; Dietel M; Denkert C; Röcken C Lancet Oncol; 2008 Feb; 9(2):139-48. PubMed ID: 18207460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]